Voluntary Withdrawal of European Authorization Based on Commercial Strategy

The European Commission (EC) has officially withdrawn the marketing authorization for 'Repaglinide Accord,' a treatment for Type 2 Diabetes Mellitus, within Europe, following a formal request from the marketing authorization holder, Accord Healthcare, on July 29, 2026. This measure is not a regulatory forced removal due to safety defects or lack of efficacy, but rather a voluntary withdrawal (Commercial Withdrawal) following the pharmaceutical company's decision to permanently discontinue sales considering commercial profitability. Although the drug obtained its initial approval from the European Medicines Agency (EMA) on December 22, 2011, and its indefinite validity was recognized in 2016, it is exiting the European market after approximately 15 years since its launch. The manufacturer has made the final decision to permanently cease the production and distribution of this generic as part of a restructuring of its mature medicine portfolio.

Meglitinide Class Mechanism and Shifting Market Paradigm

Repaglinide is a short-acting insulin secretagogue of the Meglitinide class that promotes insulin secretion by binding to the Sulfonylurea Receptor 1 (SUR1) within the ATP-sensitive potassium channel (K_ATP Channel) complex of pancreatic beta cells. While it previously gained attention for its postprandial glucose-lowering effects, its recommendation ranking in recent clinical guidelines has steadily declined due to limitations such as the risk of hypoglycemia and frequent dosing requirements. The global diabetes treatment market, which has expanded to over $65 billion, has completely shifted its prescribing paradigm toward SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1 RAs), which have demonstrated cardiovascular and renal protection benefits. Consequently, traditional oral secretagogues face the challenge of shrinking clinical demand and intensified downward pressure on prices.

Minimizing Clinical Impact through Original NovoNorm and Alternative Generic Supply

There will be no disruption to actual clinical practice or continuity of care for diabetes patients in Europe due to this withdrawal of marketing authorization. Repaglinide Accord is a generic medicine that replicates Novo Nordisk's original drug, 'NovoNorm' (US brand name Prandin). In the European market, there are sufficient authorized and distributed generic medicines with the same active ingredient from multiple pharmaceutical companies such as Krka and Teva, in addition to the original NovoNorm. Therefore, existing patients can smoothly transition their prescriptions to other generic products or newly recommended drugs according to guidelines without any supply gap.

Accelerated Restructuring of Low-Margin Portfolios by Generic Drug Manufacturers

This decision by Accord Healthcare, a generic specialist, is part of a portfolio rationalization strategy to eliminate low-profit mature items with declining margins and concentrate resources on biosimilars and high-value complex drugs. Amidst price reduction pressures in the European market and rising raw material and logistics costs due to inflation, the economic viability of meglitinide generics, which face stagnant demand, has rapidly deteriorated relative to regulatory management costs. In the global pharmaceutical industry, the strategy of reducing registration maintenance fees for mature-stage generics and reallocating R&D capabilities to highly profitable next-generation pipelines is accelerating. In conclusion, this license revocation is the result of a management decision reflecting the maximization of corporate profitability and market generational turnover, rather than regulatory risk.